OBJECTIVE: Autoantibodies are frequently found in adult patients with polymyositis (PM), dermato-myositis (DM), and overlap myositis disorders. They are less common in pediatric patients with myositis. We investigated the autoantibody pattern in a pediatric Argentine Caucasian cohort to characterize novel autoantibodies. METHODS: Sera from children that satisfied published criteria for idiopathic inflammatory myopathy were analyzed for autoantibodies by RNA and protein immunoprecipitation and immunoblotting techniques. Routine myositis-specific and myositis-associated autoantibodies as well as autoantibody specificities were determined. RESULTS: We tested sera from 64 consecutive pediatric myositis patients, including 40 with juvenile DM, 7 with juvenile PM, and 17 with overlap myositis syndromes. Sixteen (25%) patients were found to have anti-MJ autoantibody exclusively, which appears to identify a subset of pediatric myositis patients with severe disease characterized by muscle contractures and atrophy and significant compromise of functional status. Fourteen (22%) patients were found to have an antibody targeting 2 proteins of 155 and 140 kDa. Other myositis-specific autoantibodies were uncommon in this pediatric cohort. CONCLUSION: A newly recognized autoantibody, anti-MJ, was the most common antibody found in this Argentine pediatric cohort. The clinical features indicated that this antibody is distinct from other reported antibodies in pediatric patients with myositis.
OBJECTIVE: Autoantibodies are frequently found in adult patients with polymyositis (PM), dermato-myositis (DM), and overlap myositis disorders. They are less common in pediatric patients with myositis. We investigated the autoantibody pattern in a pediatric Argentine Caucasian cohort to characterize novel autoantibodies. METHODS: Sera from children that satisfied published criteria for idiopathic inflammatory myopathy were analyzed for autoantibodies by RNA and protein immunoprecipitation and immunoblotting techniques. Routine myositis-specific and myositis-associated autoantibodies as well as autoantibody specificities were determined. RESULTS: We tested sera from 64 consecutive pediatric myositispatients, including 40 with juvenile DM, 7 with juvenile PM, and 17 with overlap myositis syndromes. Sixteen (25%) patients were found to have anti-MJ autoantibody exclusively, which appears to identify a subset of pediatric myositispatients with severe disease characterized by muscle contractures and atrophy and significant compromise of functional status. Fourteen (22%) patients were found to have an antibody targeting 2 proteins of 155 and 140 kDa. Other myositis-specific autoantibodies were uncommon in this pediatric cohort. CONCLUSION: A newly recognized autoantibody, anti-MJ, was the most common antibody found in this Argentine pediatric cohort. The clinical features indicated that this antibody is distinct from other reported antibodies in pediatric patients with myositis.
Authors: Anna Rogers; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino Journal: Arthritis Care Res (Hoboken) Date: 2017-11-02 Impact factor: 4.794
Authors: Lisa G Rider; Adrienne L Yip; Iren Horkayne-Szakaly; Rita Volochayev; Joseph A Shrader; Maria L Turner; Heidi H Kong; Minal S Jain; Anna V Jansen; Chester V Oddis; Thomas A Fleisher; Frederick W Miller Journal: Clin Exp Rheumatol Date: 2014-07-28 Impact factor: 4.473
Authors: Minoru Satoh; Shin Tanaka; Angela Ceribelli; S John Calise; Edward K L Chan Journal: Clin Rev Allergy Immunol Date: 2017-02 Impact factor: 8.667